

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

1. Data from the Phase III CheckMate 057 trial evaluating nivolumab versus docetaxel for patients with nonsquamous non-small cell lung cancer (NSCLC) whose disease progressed during or after a platinum-based doublet chemotherapy demonstrated a statistically significant improvement in _____ with nivolumab.

 - a. Median overall survival
 - b. Median progression-free survival (PFS)
 - c. Both a and b
2. The Phase III J-ALEX study recently demonstrated a statistically significant improvement in PFS with _____ compared to crizotinib for patients with advanced or recurrent ALK fusion gene-positive NSCLC.

 - a. Ceritinib
 - b. Alectinib
 - c. Cabozantinib
3. The Phase IIb LUX-Lung 7 trial _____ a PFS advantage with afatinib compared to gefitinib as first-line therapy for EGFR mutation-positive advanced NSCLC.

 - a. Demonstrated
 - b. Did not demonstrate
4. In the treatment of NSCLC, osimertinib is _____.

 - a. Effective against tumors with the EGFR T790M mutation
 - b. Commonly associated with hyperglycemia
 - c. Both a and b
5. Recent data from the randomized Phase III ASCEND-4 trial evaluating first-line ceritinib versus pemetrexed for patients with Stage IIIB/IV ALK-rearranged NSCLC indicated a statistically significant improvement in PFS for the ceritinib arm.

 - a. True
 - b. False
6. Which of the following ALK inhibitors has demonstrated CNS activity in patients with NSCLC?

 - a. Alectinib
 - b. Ceritinib
 - c. Brigatinib
 - d. All of the above
7. The Phase III REVEL trial evaluating docetaxel with or without ramucirumab for patients with Stage IV NSCLC after disease progression on a platinum-based regimen demonstrated a statistically significant improvement in _____ with the addition of ramucirumab.

 - a. PFS
 - b. Overall survival
 - c. Overall response rate
 - d. Both b and c
 - e. All of the above
8. The Phase III MAPS study evaluating cisplatin and pemetrexed with or without bevacizumab for patients with newly diagnosed, unresectable malignant pleural mesothelioma reported a statistically significant improvement in median overall survival with the addition of bevacizumab.

 - a. True
 - b. False

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

9. Data from a first-in-human trial of the DLL3-targeted antibody-drug conjugate rovalpituzumab tesirine demonstrated robust responses to this agent in patients with _____.
- a. Pan-wild-type advanced NSCLC
 - b. Recurrent or refractory small cell lung cancer
 - c. Advanced mesothelioma
10. The results of the Phase III PROCLAIM trial for unresectable, locally advanced nonsquamous NSCLC did not demonstrate a statistically significant improvement in overall survival with pemetrexed/cisplatin and thoracic radiation therapy followed by consolidation pemetrexed compared to standard chemoradiation therapy for Stage III disease, although less Grade 3 and 4 toxicity was observed on the cisplatin/pemetrexed arm.
- a. True
 - b. False